MAP Pharmaceuticals to Present Data on LEVADEX™ at the 63rd Annual Meeting of the American Academy of Neurology

MOUNTAIN VIEW, Calif., Feb. 28, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that LEVADEX™ orally inhaled migraine therapy will be featured in one oral presentation and four poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii April 9-16, 2011. A summary of the Company's AAN presentations is below, and the abstracts can be accessed at the AAN website at www.aan.com. LEVADEX is an investigational acute therapy for migraine that has completed Phase 3 clinical development.

Utility of LEVADEX (MAP0004) in Situations Where Early Intervention Paradigm Is Impractical
Session Info: Platform Session: April 12, 2011, 3:00-4:30 p.m. HAST
Presentation Info: April 12, 2011 at 3:45 p.m. HAST
Presentation #: 004

An Open-Label, 2-Period, Crossover Study Comparing the Pharmacokinetics and Tolerability of LEVADEX (MAP0004, Orally Inhaled DHE) and Intravenous DHE (DHE45®) in Smoking and Non-Smoking Adult Volunteers
Session Info: Poster Session 3: April 12, 2011, 2:00-6:00 p.m. HAST
Poster #: 028

A Randomized, Double-Blind, Placebo Controlled, Three-Period Crossover Study Comparing the Acute Effects of LEVADEX (MAP0004, Orally Inhaled DHE) and Intravenous DHE on Pulmonary Arterial Systolic Pressure
Session Info: Poster Session 3: April 12, 2011, 2:00-6:30 p.m. HAST
Poster #: 029

The Major Metabolite of Dihydroergotamine (DHE) after Oral Inhalation and IV Administration Does Not Significantly Contribute to the Pharmacologic Activity
Session Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HAST
Poster #: 272

Migraine Recurrence Rates: Case for Standardization of the Definition
Session Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HAST
Poster #: 285

About LEVADEX™

LEVADEX is an investigational acute therapy for migraine that has completed Phase 3 clinical development. In the clinical trial, patients administered LEVADEX themselves using the proprietary TEMPO® inhaler. LEVADEX contains a novel formulation of dihydroergotamine (DHE). LEVADEX was evaluated in the efficacy portion of FREEDOM-301, MAP Pharmaceuticals' Phase 3 pivotal trial, which included 395 patients in the LEVADEX arm and 397 patients in the placebo arm. In the Phase 3 trial, patients taking LEVADEX therapy had statistically significant improvement at two hours compared to patients on placebo for all four co-primary endpoints: